USPTO Examiner SHIM DAVID M - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19279271Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningJuly 2025December 2025Allow400YesNo
19177721NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2025September 2025Allow500YesNo
19063141NOVEL COMPOUNDSFebruary 2025May 2025Allow200YesNo
19001374Arterial Application of Low Dose Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Transient OpeningDecember 2024April 2025Allow300YesNo
18847377NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDSeptember 2024February 2026Abandon1711NoNo
18672696PREPARATION OF PHENETHYLAMINES AND CATHINONES AND STEREOISOMERS THEREOF AND PRECURSORS THEREOFMay 2024January 2026Abandon2031NoNo
18635765LOW-SORBING GLYBURIDE FORMULATION AND METHODSApril 2024September 2025Allow1721YesNo
18628560PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITORApril 2024January 2025Allow900YesNo
18614143NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITORMarch 2024January 2026Allow2200YesNo
18597119Preparation method of glufosinate or derivatives thereofMarch 2024April 2025Allow1440YesYes
18591965HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024March 2025Abandon1320NoNo
18591753NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORSFebruary 2024September 2024Allow710YesNo
18432931PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOFFebruary 2024September 2025Allow1910YesNo
18432824METHODS AND MATERIALS FOR IMPROVING ARTERIOVENOUS FISTULA MATURATION AND MAINTAINING ARTERIOVENOUS FISTULA FUNCTIONALITYFebruary 2024October 2024Allow900YesNo
18420446FUSED RING COMPOUND HAVING UREA STRUCTUREJanuary 2024November 2024Allow1010NoNo
18392680FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEDecember 2023April 2025Allow1610YesNo
185067625-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTSNovember 2023February 2024Allow310NoNo
18495213Crystal Form Of Pyrazolyl-Amino-Pyrimidinyl Derivative, And Preparation Method Therefor And Use ThereofOctober 2023July 2024Allow910YesNo
18557458SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANTOctober 2023January 2026Allow2700NoNo
18556896CRYSTAL FORM OF THIOPHENE DERIVATIVE AND PREPARATION METHOD THEREFOROctober 2023March 2026Allow2910YesNo
18483311GLP-1 Receptor Agonists and Uses ThereofOctober 2023March 2025Allow1810NoNo
18285285Long lasting Opioid Reversal Using Hydrogen Peroxide-Induced Release in BloodOctober 2023January 2026Allow2700YesNo
18476131METHODS OF TREATING APOL-1 DEPENDENT FOCAL SEGMENTAL GLOMERULOSCLEROSISSeptember 2023July 2025Abandon2111NoNo
18469995METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORSSeptember 2023March 2025Allow1820YesNo
18462780TRICYANOHEXANE PURIFICATION METHODSSeptember 2023June 2025Allow2200YesNo
18448150A LYOPHILIZED PHARMACEUTICAL COMPOSITIONAugust 2023November 2023Allow300YesNo
18263481ANTIVIRAL AGENTS AND USES THEREOFJuly 2023December 2025Allow2800YesNo
18225859LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTSJuly 2023November 2025Allow2800YesNo
18346342Salts of Obicetrapib and Processes for their Manufacture and Intermediates ThereofJuly 2023March 2024Allow911YesNo
18334385SULFAMATE MODULATORS OF PIN1 ACTIVITY AND USES THEREOFJune 2023February 2026Allow3201YesNo
18265422LOX ENZYME INHIBITING METHODS AND COMPOSITIONSJune 2023February 2024Allow810NoNo
18327647cGAS INHIBITORSJune 2023October 2025Allow2900YesNo
18038802PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORSMay 2023October 2025Allow2900YesNo
18318760RIPK1 INHIBITORS AND METHODS OF USEMay 2023September 2025Allow2800YesNo
18315267IRAK DEGRADERS AND USES THEREOFMay 2023April 2024Abandon1101NoNo
181372812,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONES USEFUL AS INHIBITORS OF DHODHApril 2023July 2025Allow2720YesNo
18249762Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related TheretoApril 2023October 2025Allow3000YesNo
18136765POLYMORPHISMS OF HM30181 MESYLATEApril 2023November 2024Allow1901YesNo
18134735PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEApril 2023September 2023Allow501YesNo
18134894BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOFApril 2023August 2023Allow401YesNo
18134747PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEApril 2023May 2024Allow1340YesNo
18247139HSD17B13 INHIBITORS AND USES THEREOFMarch 2023March 2026Abandon3601NoNo
18126765PYRIDO[3,4-b]INDOL-1-ONE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023August 2023Allow400YesNo
18187487METHODS OF TREATING OPHTHALMIC CONDITIONS WITH ENHANCED PENETRATION COMPOSITIONS OF BIMATOPROST AND TIMOLOLMarch 2023May 2025Abandon2640NoNo
180417191H-BENZO[D]IMIDAZOLE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSISFebruary 2023September 2025Allow3100YesNo
18011499Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivativesDecember 2022September 2025Allow3201YesNo
18000945ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMODDecember 2022March 2026Allow3911YesNo
18008399NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USEDecember 2022November 2025Abandon3501NoNo
17923899TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDSNovember 2022December 2025Abandon3701NoNo
17967273PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASESOctober 2022April 2025Allow2901YesNo
17967342INHIBITORS OF AV ß6 INTEGRINOctober 2022November 2025Allow3711YesNo
17955730COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALSSeptember 2022October 2025Allow3620YesNo
17906946BUCCAL AND ENTERIC DELIVERY OF FATTY ACIDS IN FOODS AND BEVERAGESSeptember 2022May 2025Allow3100YesNo
17822494COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES, COMPRISING CHLORPROMAZINEAugust 2022July 2024Abandon2320NoNo
17799950PRAMIPEXOLE HYDROCHLORIDE ORAL LIQUIDAugust 2022March 2023Allow700YesNo
17785646ANTHELMINTIC COMPOUNDS COMPRISING AZAINDOLES STRUCTUREJune 2022July 2025Allow3710NoNo
17840532SYNERGISTIC COMPOSITION FOR ACTIVATING INTRACELLULAR SECONDARY MESSENGER(CAMP) PATHWAYJune 2022December 2024Allow3170YesNo
17831469FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOFJune 2022September 2023Allow1610NoNo
17752609COMBINATION THERAPIESMay 2022August 2024Allow2711YesNo
17741356VENETOCLAX DOSING REGIMENS FOR USE IN TREATING MYELODYSPLASTIC SYNDROMES IN COMBINATION WITH A CYP3A INHIBITOR AND AZACITIDINEMay 2022January 2026Abandon4440NoNo
17735011ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDSMay 2022January 2024Allow2111NoNo
17727125COMPOUNDS FOR TREATING PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) MEDIATED DISEASES OR CONDITIONSApril 2022September 2023Abandon1701NoNo
17659558PHARMACOLOGICAL TREATMENT OF AUTISM SPECTRUM DISORDERApril 2022March 2024Abandon2310NoNo
17714298HETEROCYCLIC RED AZO COLORANTS FOR SEED TREATMENT APPLICATIONSApril 2022February 2025Allow3511NoNo
17710050N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOFMarch 2022January 2025Allow3421YesNo
17707297LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTSMarch 2022May 2023Allow1300YesNo
17705155PROCESSES FOR PREPARING 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDEMarch 2022November 2025Allow4410NoNo
17689969Intraarterial (IA) Application of Low Dose of Ethyl Alcohol Enables Blood-Brain Barrier (BBB) Impermeable Therapeutics Brain EntryMarch 2022June 2025Allow4051YesNo
17683470COMBINATION THERAPY USING A MALT1 INHIBITOR AND A BTK INHIBITORMarch 2022July 2024Abandon2920YesNo
17638341CRYSTALLINE FORMS OF A CD73 INHIBITORFebruary 2022June 2025Abandon4001NoNo
17637426THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDSFebruary 2022September 2025Allow4310YesNo
17636634PROCESS FOR THE PREPARATION OF APALUTAMIDEFebruary 2022October 2025Abandon4401NoNo
17635421MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERSFebruary 2022March 2026Abandon4911NoNo
17650555ANALGESIC FORMULATION FOR PERINEAL PAINFebruary 2022September 2023Abandon1911NoNo
17667519Neurologist Formulated Nocturnal Nootropic Founded on a Novel Theory of Brain AgingFebruary 2022October 2025Abandon4501YesNo
17587565METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASEJanuary 2022February 2025Allow3741NoNo
17629899COCRYSTALS OF POSACONAZOLE, METHODS OF MAKING AND USING SAMEJanuary 2022June 2025Allow4001YesNo
17582728FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASEJanuary 2022April 2023Allow1500YesNo
17624970PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATEJanuary 2022March 2025Allow3811YesNo
17597165IRAK DEGRADERS AND USES THEREOFDecember 2021July 2025Allow4211YesNo
17616614IRSOGLADINE FOR THE TREATMENT OF EOSINOPHILIC GASTROINTESTINAL DISEASESDecember 2021July 2025Allow4410YesNo
17615337MONTELUKAST SALTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAMENovember 2021August 2025Allow4421YesNo
17615437METHOD FOR SYNTHESIZING FUROIMIDAZOPYRIDINE COMPOUND, POLYMORPHIC SUBSTANCE AND POLYMORPHIC SUBSTANCE OF SALTNovember 2021March 2025Allow3901YesNo
17614921LIQUID COMPOSITION COMPRISING MEFENTRIFLUCONAZOLENovember 2021May 2025Abandon4201NoNo
17613239HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOFNovember 2021September 2025Abandon4611NoNo
17513448POLYMORPHISMS OF HM30181 MESYLATEOctober 2021March 2023Allow1700YesNo
17513284METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORSOctober 2021March 2023Allow1700YesNo
17439638HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIASeptember 2021March 2025Allow4211YesNo
17427269INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITORJuly 2021December 2024Abandon4110NoNo
17288982Combination Therapies For Treating CancerApril 2021November 2025Allow5531YesNo
17288742COMPOSITIONS AND METHODS FOR TREATING GOUT AND HYPERURICEMIAApril 2021August 2024Abandon3910NoNo
17283646MST1 KINASE INHIBITOR AND USE THEREOFApril 2021February 2025Allow4621YesNo
17283754METHODS FOR TREATING OR PREVENTING SKIN CONDITIONSApril 2021December 2025Abandon5721NoNo
17283724MALONATE SALT OF VARLITINIBApril 2021August 2024Abandon4011NoNo
17283151TYK2 KINASE INHIBITORSApril 2021August 2024Allow4110YesNo
17282277COVALENT TARGETING OF E3 LIGASESApril 2021June 2024Allow3901YesNo
17215959PYRAZOLE PYRIMIDINE DERIVATIVE AND USES THEREOFMarch 2021October 2023Allow3110YesNo
17280628CONDENSED-CYCLIC COMPOUNDMarch 2021July 2024Allow4001YesNo
17213362CINNOLINE COMPOUNDS AND USES THEREOFMarch 2021December 2024Abandon4521NoNo
17280211Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative DiseasesMarch 2021February 2025Abandon4711NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHIM, DAVID M..

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner SHIM, DAVID M. - Prosecution Strategy Guide

Executive Summary

Examiner SHIM, DAVID M. works in Art Unit 1626 and has examined 62 patent applications in our dataset. With an allowance rate of 58.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner SHIM, DAVID M.'s allowance rate of 58.1% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by SHIM, DAVID M. receive 1.23 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SHIM, DAVID M. is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +83.2% benefit to allowance rate for applications examined by SHIM, DAVID M.. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.6% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 7.7% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Petition Practice

When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.